MoonLake Immunotherapeutics
MLTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. With a market capitalization of $1.01B, it sits in small-cap territory. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Market Cap
$1.01B
Beta
1.08
P/E (TTM)
—
P/E (Fwd)
-3.56
EPS (TTM)
$-3.83
EPS (Fwd)
$-3.33
ROE
-67.5%
ROA
-32.4%
Cash
$537.0M
Total Debt
$101.5M
Free CF
-$131.9M
52W Change
17.7%
Annual Financials
Cash vs Debt
Where MLTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MLTX finished 41.41% below its 150-day moving average ($16.64) and 41.23% below its 200-day moving average ($16.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MLTX overbought or oversold?
At the October 20, 2026 close, MLTX's RSI(14) was 24.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $537.0M in cash and $101.5M in debt, MLTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$131.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -67.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, MLTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MLTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.